Chief scientific officer named first Richard L. Menschel Research Chair at Special Surgery

December 13, 2011

Steven R. Goldring, M.D., chief scientific officer, has been named the first Richard L. Menschel Research Chair at Hospital for Special Surgery. A gift of $5 million from an anonymous donor will permanently endow the position of the Hospital's chief scientific officer.

This chair honors Richard L. Menschel, Hospital for Special Surgery chairman emeritus and a senior director, The Goldman Sachs Group, L.P., who has been a vital proponent of the Hospital's focus on research. In addition to providing leadership for the HSS Reseach Division, Dr. Goldring's research objective is to translate basic research into new therapies for people with mobility disorders, with a focus on expanding the Hospital's clinical registries and advancing its Osteoarthritis Initiative.

"Extraordinary advances in medicine can be accomplished when there are partnerships between visionary leaders like Richard Menschel and scientific innovators like Dr. Steven Goldring," said Louis A. Shapiro, president and CEO of Hospital for Special Surgery.

Dr. Goldring is a strong advocate of the physician-scientist. He has led the recruitment of talented scientists in the areas of arthritis and tissue degeneration, autoimmunity and inflammation, musculoskeletal integrity, and tissue engineering, regeneration and repair.

"I am truly honored to be the first holder of the Richard L. Menschel Research Chair at Hospital for Special Surgery," said Dr. Goldring. "I began my career as a clinician, but I was also fortunate enough to be in an environment that supported and promoted the great importance of research. While our focus is how best to define disease mechanisms, the ultimate goal is to apply what we learn to patient care."

A major initiative that Dr. Goldring will oversee is the expansion of Hospital for Special Surgery's clinical patient registries. These powerful research tools provide the foundation of clinical trials, providing an ongoing collection of confidential clinical and demographic information that can be analyzed to examine health care issues that are critical to understanding the outcome of patient care and refining treatments.

"During his tenure Dr. Goldring has taken the Research Division to new levels," said Thomas Sculco, M.D., surgeon-in-chief at Hospital for Special Surgery. "His exceptional background as a physician and researcher in arthritic conditions and bone and joint disorders makes him uniquely qualified to lead the Hospital in all areas of investigation."

"A priority for any first-rate medical institution is to have a world-class research program," said Mr. Menschel. "Dr. Goldring has led Hospital for Special Surgery into a new era of clinical and translational research."

Dr. Goldring's research focuses on understanding the cellular and genetic mechanisms involved in the regulation of bone remodeling--the process of bone recycling that occurs normally in the body, but is often impaired and altered in certain bone disorders. The ultimate goal of his research is to develop more effective approaches for some of our most difficult to treat orthopedic disorders, including osteoporosis, rheumatoid arthritis and osteoarthritis, the most common form of arthritis.

Hospital for Special Surgery's Osteoarthritis Initiative is focused on preventing and treating this chronic debilitating illness that limits the mobility and impairs the quality of life of 27 million Americans. The Initiative aims to achieve advances in understanding, preventing, diagnosing and treating osteoarthritis through a multidisciplinary approach that involves collaboration among specialties.

Dr. Goldring came to Hospital for Special Surgery in 2006 from Harvard Medical School where he was chief of rheumatology at Beth Israel Deaconess Medical Center and New England Baptist Hospital, Boston. In addition, he served as professor of medicine at Harvard Medical School. He was also director of research at the New England Baptist Bone and Joint Institute at Harvard Institutes of Medicine.
-end-
About Hospital for Special Surgery

Founded in 1863, Hospital for Special Surgery (HSS) is a world leader in orthopedics, rheumatology and rehabilitation. HSS is nationally ranked No. 1 in orthopedics, No. 2 in rheumatology, No. 19 in neurology, and No. 16 in geriatrics by U.S.News & World Report (2011-12), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center three consecutive times. HSS has one of the lowest infection rates in the country. From 2007 to 2011, HSS has been a recipient of the HealthGrades Joint Replacement Excellence Award. HSS is a member of the NewYork-Presbyterian Healthcare System and an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.

For more information contact:
Andrew Klein
212-774-2014
KleinA@hss.edu

Phyllis Fisher
212-606-1197
FisherP@hss.edu

Hospital for Special Surgery

Related Osteoarthritis Articles from Brightsurf:

Major savings possible with app-based osteoarthritis treatment
Osteoarthritis treatment conducted digitally via an app costs around 25% of what conventional care costs, according to a study from Lund University in Sweden published in the research journal PLOS ONE.

New approach to treating osteoarthritis advances
Injections of a natural 'energy' molecule prompted regrowth of almost half of the cartilage lost with aging in knees, a new study in rodents shows.

Bone drug may be beneficial for knee osteoarthritis
Bisphosphonates (a class of drugs that prevent the loss of bone density and used to treat osteoporosis and similar diseases) appear to be safe and beneficial for osteoarthritis patients.

Certain jobs linked to higher risk of knee osteoarthritis
Workers in jobs that typically involve heavy lifting, frequent climbing, prolonged kneeling, squatting, and standing face an increased risk of developing knee osteoarthritis.

App helps reduce osteoarthritis pain
By performing a few simple physical exercises daily, and receiving information about their disease regularly, 500 osteoarthritis patients were able to on average halve their pain in 6 months -- and improve their physical function.

Osteoarthritis can increase your risk for social isolation
In a study published in the Journal of the American Geriatrics Society, researchers examined information from the European Project on OSteoArthritis (EPOSA) study.

High rates of opioid prescriptions for osteoarthritis
Opioids work against severe pain but the risks of side effects and addiction are high.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

3D printing may help treat osteoarthritis
In a Journal of Orthopaedic Research study, scientists used 3D printing to repair bone in the joints of mini-pigs, an advance that may help to treat osteoarthritis in humans.

Finger joint enlargements may be linked to knee osteoarthritis
Heberden's nodes (HNs) are bony enlargements of the finger joints that are readily detectable in a routine physical exam and are considered hallmarks of osteoarthritis.

Read More: Osteoarthritis News and Osteoarthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.